Logo
Homepage
Explore Our Models
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Metabolism & Obesity
Unveiling the Secrets of the DIO-B6-M Mouse Model for Obesity Research
Cyagen Technical Content Team | June 11, 2025
Explore Ready-to-Use Mouse Models in MouseAtlas
Discover our extensive library of KO, cKO, and disease-specific mouse models. Accelerate your research with study-ready animals validated by scientists worldwide.
Explore Ready-to-Use Mouse Models in MouseAtlas
Contents
01. What is the Diet-Induced Obesity (DIO) Mouse Model? 02. How Does Weight and Blood Glucose Change in DIO Mice? 03. Increased NK Cells and Macrophages in DIO Mice Show Inflammation 04. Elevated Blood Lipids and Liver Function Markers in DIO Mice 05. Semaglutide Treatment for Obesity 06. Why Choose the DIO-B6-M Mouse Model for Obesity Research?

Obesity has become a global health issue. According to statistics, 2.5 billion adults were classified as overweight in 2022, with over 890 million suffering from obesity. Since 1990, the global adult obesity rate has more than doubled, and the adolescent obesity rate has tripled.[1] Obesity can lead to a range of severe complications, including cardiovascular diseases (CVD), gastrointestinal disorders, type 2 diabetes (T2D), and respiratory diseases. Developing animal models that can simulate the pathological characteristics of human obesity and metabolic syndromes is a key tool for obesity research.

What is the Diet-Induced Obesity (DIO) Mouse Model?

The inbred strain C57BL/6 mice are widely used to establish diet-induced obesity (DIO) mouse models by feeding them a high-fat diet. Studies have shown that compared to C57BL/6N mice, C57BL/6J mice carry a deletion of exons 7-11 of the Nnt gene. The loss of function of this gene can result in mitochondrial metabolic dysfunction in pancreatic β-cells and impaired insulin secretion. In fact, C57BL/6J mice exhibit glucose intolerance and reduced insulin secretion,[2-4] making them less ideal for studying metabolic diseases.

The Role of Nnt Gene Deficiency in Drug Research and the Development of the DIO-B6-M Mouse Model

The Nnt gene is predicted to be involved in NAD binding activity, NAD(P)+ transhydrogenase activity, and NADP binding activity, suggesting that its deficiency may affect drug research involving NADPH-related mechanisms. Therefore, Cyagen has developed the DIO-B6-M mice (Product Code: C001549) on the C57BL/6NCya background, induced by a 60% high-fat diet. This model is suitable for studying obesity, diabetes, inflammation, fatty liver, and other metabolic diseases, as well as for the screening and preclinical efficacy evaluation of related therapeutic drugs.

How Does Weight and Blood Glucose Change in DIO Mice?

At 4 weeks of age, male C57BL/6NCya mice began a 60% high-fat diet after a one-week acclimatization period of adaptive feeding. Body weight was monitored regularly, and random blood glucose levels were measured after 25 weeks of high-fat feeding. Results showed that mice in the high-fat diet (HFD) group had significantly higher body weight and random blood glucose levels compared to the normal diet (ND) group.

Figure 1: Body Weight Monitoring and Blood Glucose Test Results of DIO-B6-M Mice

Increased NK Cells and Macrophages in DIO Mice Show Inflammation

After 25 weeks of high-fat feeding, there was a marked increase in the number of NK cells and macrophages in the peripheral blood of DIO-B6-M mice, indicating an elevated inflammatory response.

Figure 2: Flow Cytometry Analysis of Immune Cells (T Cells, B Cells, NK Cells, and Macrophages) in the Peripheral Blood of Mice After 25 Weeks of HFD Induction

Elevated Blood Lipids and Liver Function Markers in DIO Mice

At the 25-week mark, DIO-B6-M mice had significantly elevated levels of total cholesterol (T-CHO), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), as well as aspartate transaminase (AST) and alanine transaminase (ALT), compared to the ND group.

Figure 3: Blood Lipid and Liver Function Indicators in Mice After 25 Weeks of Diet Induction

(TG: Triglycerides; T-CHO: Total Cholesterol; HDL-C: High-Density Lipoprotein Cholesterol; LDL-C: Low-Density Lipoprotein Cholesterol; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase)

Semaglutide Treatment for Obesity

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a drug used to treat diabetes by mimicking the naturally occurring GLP-1 hormone to promote insulin secretion, inhibit glucagon release, and slow gastric emptying, thereby reducing appetite. In addition to its use in diabetes treatment, it is also being studied for its weight-loss effects, especially in obese patients. Its effectiveness in promoting weight loss has made it a highly regarded drug.

Semaglutide Reduces Obesity in DIO Mice

In this study, DIO-B6-M mice were fed a 60% high-fat diet for 12 weeks and then received subcutaneous injections of Semaglutide twice a week. The blank group (B6N+ND) and the control group (B6N+HFD) were injected with the same dose of a control solvent. The results showed that Semaglutide treatment significantly reduced body weight, blood glucose levels, and food intake, while improving glucose tolerance in the DIO-B6-M mice.

Figure 4: DIO-B6-M Mice Can Be Used for Screening of Related Therapeutic Drugs and Preclinical Efficacy Evaluation

Why Choose the DIO-B6-M Mouse Model for Obesity Research?

The DIO-B6-M mouse model (product code: C001549) is a valuable tool for the research of obesity, diabetes, and other metabolic diseases and related drug development.

DIO-B6-M mice (Product Code: C001549) are developed on the C57BL/6NCya background —avoiding metabolic Nnt gene mutation effects seen in C57BL/6J strain backgrounds — and induced through a 60% high-fat diet starting from 4 weeks of age. These DIO mouse models exhibit phenotypes such as increased body weight, elevated random blood glucose levels, an increase in NK cells and macrophages, as well as elevated blood lipid and liver function indicators. They can be used for research on metabolic diseases such as obesity and diabetes.

Explore Cyagen’s Range of Metabolic and Cardiovascular Disease Models

In addition to the DIO-B6-M model, Cyagen offers a wide range of metabolic disease models and humanized models to meet researchers' needs in metabolic-related studies. Contact us today to learn how our models can support your research into obesity, diabetes, cardiovascular disease, and related metabolic diseases.

Recommended Gene Edited Models for Metabolic and Cardiovascular Disease Research

Product Number Product Name Strain Background Application
C001507 B6J-Apoe KO C57BL/6JCya Atherosclerosis, Hypercholesterolemia, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
C001067 APOE C57BL/6NCya Atherosclerosis
C001291 B6-db/db C57BL/6JCya High Blood Sugar and Obesity
C001392 Ldlr KO (em) C57BL/6JCya Familial Hypercholesterolemia
C001368 B6-ob/ob(Lep KO) C57BL/6JCya Type 2 Diabetes and Obesity
C001232 Uox KO C57BL/6JCya Hyperuricemia
C001393 Uox-KO (Prolonged) C57BL/6JCya Hyperuricemia
C001267 Atp7b KO C57BL/6NCya Copper Metabolism Disorder, Wilson's Disease
C001265 Foxj1 KO C57BL/6NCya Primary Ciliary Dyskinesia
C001266 Usp26 KO C57BL/6NCya Klinefelter Syndrome
C001273 Fah KO C57BL/6NCya Phenylketonuria Type 1
C001383 Alb-Cre/LSL-hLPA C57BL/6NCya Cardiovascular Targets
C001421 B6-hGLP-1R C57BL/6NCya Metabolic Targets
C001400 B6J-hANGPTL3 C57BL/6JCya Metabolic Targets
C001493 FVB-Abcb1a&Abcb1b DKO (Mdr1a/b KO) FVB Diseases Related to Blood-Brain Barrier Permeability
C001532 Serping1 KO C57BL/6JCya Hereditary Angioedema(HAE)

Other Models for Metabolic and Cardiovascular Disease Research: Spontaneous, Induced, Composite, & Surgical Models

Diet-Induced Obesity (DIO) Model Type 2 Diabetes Mellitus (T2DM) Models Type 1 Diabetes Mellitus (T1DM) Models Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Model
Chemically Induced MASLD Model MASLD Model Composite MASLD Model Composite Arteriosclerosis Model
Arteriosclerosis Model Acute Pancreatitis Model Chronic Pancreatitis Model DIO&CCL4 Induced MASH(NASH) Mouse Model

References:

[1] World Health Organization (WHO). (2024, March 1). Obesity and overweight. Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

[2] Simon MM, Greenaway S, White JK, Fuchs H, Gailus-Durner V, Wells S, Sorg T, Wong K, Bedu E, Cartwright EJ, Dacquin R, Djebali S, Estabel J, Graw J, Ingham NJ, Jackson IJ, Lengeling A, Mandillo S, Marvel J, Meziane H, Preitner F, Puk O, Roux M, Adams DJ, Atkins S, Ayadi A, Becker L, Blake A, Brooker D, Cater H, Champy MF, Combe R, Danecek P, di Fenza A, Gates H, Gerdin AK, Golini E, Hancock JM, Hans W, Hölter SM, Hough T, Jurdic P, Keane TM, Morgan H, Müller W, Neff F, Nicholson G, Pasche B, Roberson LA, Rozman J, Sanderson M, Santos L, Selloum M, Shannon C, Southwell A, Tocchini-Valentini GP, Vancollie VE, Westerberg H, Wurst W, Zi M, Yalcin B, Ramirez-Solis R, Steel KP, Mallon AM, de Angelis MH, Herault Y, Brown SD. A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol. 2013 Jul 31;14(7):R82.

[3] Freeman H, Shimomura K, Horner E, Cox RD, Ashcroft FM. Nicotinamide nucleotide transhydrogenase: a key role in insulin secretion. Cell Metab. 2006 Jan;3(1):35-45.

[4] Hull RL, Willard JR, Struck MD, Barrow BM, Brar GS, Andrikopoulos S, Zraika S. High fat feeding unmasks variable insulin responses in male C57BL/6 mouse substrains. J Endocrinol. 2017 Apr;233(1):53-64.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
Unveiling the Secrets of the DIO-B6-M Mouse Model for Obesity Research
Spinocerebellar Ataxia Type III (SCA3) Research Model—B6-hATXN3 Mice
Vision Stolen by Years - Age-related Macular Degeneration
Y Maze Behavioral Task: Studying the function of spatial learning and memory in Neuroscience research
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest